Cannabis and Cannabinoid Research

The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder?

Role of Steroids on the Membrane Binding Ability of Fatty Acid Amide Hydrolase

Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature

Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease

Role of Cannabinoids and Terpenes in Cannabis-Mediated Analgesia in Rats.

The Impact of Perioperative Cannabis Use: A Narrative Scoping Review.

Fast and Sensitive Quantification of Δ9-Tetrahydrocannabinol and Its Main Oxidative Metabolites by Liquid Chromatography/Tandem Mass Spectrometry

Reduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis

A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain

Pharmacokinetic and Pharmacodynamic Characterization of Tetrahydrocannabinol-Induced Cannabinoid Dependence After Chronic Passive Cannabis Smoke Exposure in Rats.

Cannabis Consumption in People Living with HIV: Reasons for Use, Secondary Effects, and Opportunities for Health Education.

Systemic Blockade of the CB1 Receptor Augments Hippocampal Gene Expression Involved in Synaptic Plasticity but Perturbs Hippocampus-Dependent Learning Task.

Potency Analysis of Medical Marijuana Products from New York State

Cannabinoids, Pain, and Opioid Use Reduction: The Importance of Distilling and Disseminating Existing Data.

Anandamide Is Related to Clinical and Cardiorespiratory Benefits of Aerobic Exercise Training in Migraine Patients: A Randomized Controlled Clinical Trial.

Altered Swimming Behaviors in Zebrafish Larvae Lacking Cannabinoid Receptor 2

Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders

Correction to: CB1 Allosteric Modulator Org27569 Is an Antagonist/Inverse Agonist of ERK1/2 Signaling, by Gamage TF, Anderson JC, and Abood ME. Cannabis Cannabinoid Res. 2016;1(1):272-280. DOI: 10.1089/can.2016.0028.

2-Linoleoylglycerol Is a Partial Agonist of the Human Cannabinoid Type 1 Receptor that Can Suppress 2-Arachidonolyglycerol and Anandamide Activity.